PEPTIDE THERAPY

Drug Discovery & Development

We specialize in the discovery and development of peptide-based therapeutics. We have built a versatile and accelerated discovery engine capable of addressing targets across diverse proteins and receptors. Our platform supports both existing peptide backbone libraries and de novo discovery, giving us the flexibility to tailor approaches to a wide range of biological challenges.

Driving Peptide Therapeutics

Versatile, target-agnostic peptide discovery platform capable of addressing a wide range of receptor and protein targets
Rapid high-throughput peptide screening leveraging automation and smart design
Accelerated development candidate selection typically achieved within 12-15 months
Expertise-driven, translatable in vivo pharmacology across multiple therapeutic areas

Consult with Niels Vrang

Co-founder & Scientific Advisor

Choose the right, trustworthy discovery partner.

Accelerated Peptide Therapeutic Innovation

Whether building on established peptide frameworks or venturing into novel chemical space, our integrated platform, StreaMLine, delivers precision, speed, and scalability to accelerate peptide-based therapeutic innovation. Through advanced in-house disease models, imaging technologies, and discovery tools, we generate high-resolution, translational insights that enable robust in vivo validation and data-rich decision-making — ultimately building confidence early in clinical development.

Key Capabilities

Target-Agnostic
Discovery

Applicable to a broad spectrum of proteins and receptors

High-Throughput Screening 

Using a combination of automated assays, integrated wetlab screening, and smart design strategies

Machine Learning-Driven Optimization

Allowing us to prioritize the most promising candidates

Accelerated
Timelines

From screening initiation to development candidate selection in 12-15 months

Advanced In Vivo Pharmacology

Across a growing portfolio of advanced animal models and 3D imaging technologies

Translational Clinical Trials

Early trials that explore, validate, and inform

Wet lab exploration powered by explainable AI

The streaMLine platform

streaMLine is a machine learning-based peptide drug discovery platform developed at Gubra to streamline the design, synthesis, screening, and optimization of therapeutic peptides. It was purpose-built to overcome limitations in peptide drug development such as short half-life, instability, and poor solubility, by harnessing high-throughput data generation and computational modeling.

Explore the streaMLine platform

NEXT-GENERATION PEPTIDE DRUG DEVELOPERS

End-to-End Expertise in Peptide Discovery and Development

Peptide synthesis

Automated, parallel solid-phase peptide synthesis to rapidly generate large peptide synthesis of customized peptide libraries, producing over 4,000 peptides per month. Generating linear and cyclic peptides, incorporating natural and unnatural amino acids, half-life extenders, and linkers. Peptides are directly analyzed without further purification, accelerating data generation for machine learning–driven drug design.

In vitro pharmacology

A wide range of in vitro assays, including cellular, non-cellular, and enzymatic assays to assess the pharmacological properties of peptide drug candidates. These assays are designed to evaluate factors such as potency and binding affinities. These assays supports Gubra’s highly automated drug screening platform, enabling rapid and efficient assessment of compound attributes.

Bioanalysis

Our bioanalysis capabilities feature advanced analytical platforms for precise quantification and comprehensive pharmacokinetic profiling, delivering reliable data essential for confidently advancing drug candidates.

CMC

Our platform enables selection for key CMC properties, including chemical and plasma stability, solubility, and fibrillation resistance to ensure durability, formulation viability, and reduced aggregation risk. Eventually, enabling rapid, high-quality candidate selection ready for clinical development.

In vivo pharmacology

Highly translatable advanced rodent models across metabolic, fibrotic, inflammatory, CNS, respiratory disease areas. Supported by cutting-edge bioanalysis, and state-of-the-art imaging technologies.

Data management and analysis

Data management and analysis are central to advancing drug discovery and preclinical research. Our specialized team of data scientists and software developers harnesses AI-driven approaches to optimize compound design and extract deep biological insights. By automating statistical analyses and enabling interactive exploration of complex datasets, we ensure data quality, reproducibility, and faster, more informed decision-making.